Beliard, K, Ebekozien, O, Demeterco-Berggren, C, Alonso, T, Gallagher, M, Clements, M, Rapaport, R

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) global pandemic has marked 2020. There have been initial reports on coronavirus disease 2019 (COVID-19) association with diabetes mellitus and diabetic ketoacidosis (DKA).1

Early diabetogenic effect of COVID-19 and glucose homeostasis is postulated to be due to the angiotensin-converting enzyme 2–mediated damage of the pancreatic islet cells, leading to hyperglycemia associated with underproduction of insulin.2

There might also be increased demand for insulin and increased insulin resistance related to cytokine release following COVID-19. An international registry has been established to further understand the different mechanisms and types of diabetes that might co-occur during or after COVID-19.

This report focuses on patients with newly diagnosed type 1 diabetes (T1D) simultaneously presenting with COVID-19 in comparison with a cohort of newly diagnosed patients that tested negative for COVID-19 during the same period.

Click here to view the article!

If you are a member of the T1DX-QI, you can view the full pdf in the portal.